Allergan Launches Generic Version of Invega

Allergan plc announced on Friday that it has launched a generic version of Janssen’s Invega (paliperidone extended-release tablets) in the U.S.  

Allergan says that it is the first company to receive FDA approval for and launch a generic version of Invega, demonstrating the deep expertise of its global generics R&D, regulatory and supply chain teams.

“This launch reinforces Allergan’s commitment to developing, manufacturing and bringing to market high-quality, affordable versions of challenging products like Invega, benefiting patients and reducing healthcare costs,” said Robert Stewart, Allergan’s Executive Vice President & President, Generics and Global Operations.

Allergan notes that Invega extended-release tablets are indicated for the treatment of schizophrenia in adults and adolescents (12-17 years of age).